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ROLE OF LYMPHOCYTE RECOVERY AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION IN PREDICTING RELAPSE IN
PEDIATRIC ACUTE LEUKIMIAS
Afzal, S.1, Ishaqi, M.K.1, Dupius, A.2, Doyle, J.1, Gassas, A.1 1Division
of Heamatology and Oncology/BMT, Hospital for Sick Children, To-
ronto, ON, Canada; 2Division of Clinical Research Support Unit, To-
ronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a
curative treatment for many children with relapsed or high risk
acute leukemias both myelogenous (AML) and lymphoblastic
(ALL). There are no reliable markers to predict relapse which
remain main cause of treatment failure post transplantation with
very poor outcome. We hypothesize that early lymphocyte recov-
ery measured by the absolute lymphocyte count (ALC) after
HSCT correlate with relapse and survival. Therefore, we evaluated
the effect of ALC and risk of relapse by studying ALC on day
21(ALC-21) and day 30(ALC-30) post HSCT in both ALL and
AML children. We reviewed 207 consecutive patients with acute
leukemias who received allogeneic HSCT between 1994 and 2005
in the Hospital for Sick Children, Toronto, Canada. One-thirty-
six transplantations were performed for ALL and 75 transplanta-
tions were performed for 71 children with AML. All patients at
time of HSCT were in complete morphological remission (CR)
except for one AML patient. Remission status were as follows;
CR1, n84; CR2, n103; CR3, n23 and one patient with AML
had 10% blast just prior to HSCT. Conditioning regimens in-
cluded; cylcophosphamide/TBI in 110 patients, VP16 and TBI in
59 patients, busulphan and cyclophosphamide in 28 patients and 14
children received other conditioning regimens. Donor stem cells
source were; matched sibling donor (MSD) in 98 patients, a mis-
matched related donor (MMRD) in 21 patients, and 88 children
received matched unrelated donor (MUD) and 4 children received
cord progenitor stem cells. For ALL, patients with ALC
0.3109/L at day 21 (n104) had more than 5 times risk of
relapse compared to those with ALC count 0.3  109/L (n32)
(Hazard ratio 1/0.19; P0.0004). Patients with ALC 0.310/L
(n48) at day 30 were more than twice likely to relapse compared
to those with ALC 0.3109/L (n88) (Hazard ratio 1/0.46;
P0.01). Whereas in AML; ALC 0.3109/L or 0.3109/L on
day 21 and 30 were not predictive of relapse with a Hazard ratio at
day 21; 0.88; P 0.8), Hazard ratio at day 30; 0.5; P 0.2. Con-
clusion: Slow lymphocyte recovery after HSCT appears to be
associated with a signiﬁcantly high risk of relapse in ALL but not
in AML as analyzed on day 21 and day 30 post HSCT. This group
of patients in ALL may beneﬁt from post transplant immune
manipulation to prevent relapse. However, in AML early lympho-
cyte recovery is not predictive of relapse.
221
A SUBMYELOABLATIVE REGIMEN OF CAMPATH-1H AND FLUDARABINE
FOR PATIENTS WITH GRAFT FAILURE FOLLOWING ALLOGENEIC
TRANSPLANTATION FROM MHC IDENTICAL OR NEAR IDENTICAL DO-
NORS
Ahmed, N.1, Leung, K.S.1, Bollard, C.M.1, Gottschalk, S.1,
Myers, G.D.1, Carrum, G.2, Heslop, H.E.1, Brenner, M.K.1,
Krance, R.A.1 1Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX.
Primary or secondary graft failure or the persistence or reappear-
ance of mixed chimerism (MC) are potentially serious causes of
morbidity and mortality following hematopoietic stem cell trans-
plantation (HSCT). In a phase I/II pilot study we combined Flu-
darabine with the lympho-depleting humanized anti-CD52 anti-
body Campath-1H as a non-myeloablative therapy designed to
overcome donor-anti-recipient T cell responses and to permit
complete and successful donor engraftment following re-infusion
of donor stem cells. This study evaluated the safety, feasibility, and
rate of donor engraftment for twenty-two patients at our institution
from September 2000 to June 2006 (median age 3.5 years; range 7
months to 69 years; 14 males) with engraftment failure or mixed
chimerism (range 8-61% donor cell chimerism). All patients had
previously received one or more transplants for lympho-hemato-
logic malignancies (n14), immunodeﬁciency syndromes (n5) or
metabolic diseases (n3). Twelve patients were enrolled for graft
failure (55%) and ten for mixed chimerism (45%). Seven patients
were transplanted in relapse (3 with graft failure and 4 with mixed
chimerism). The conditioning regimen consisted of Fludarabine
and Campath-1H (30mg/m2/day and 10mg/day, respectively)
given on days –5 to –3. Twelve patients received transplants from
a single antigen mismatched family donor (55%), nine from a
matched unrelated (41%) and one from an HLA-identical sibling.
Donors were the same used for the primary transplant. Twenty-one
evaluable patients (95%) achieved sustained neutrophil engraft-
ment, and complete donor chimerism by day 28. Regimen-related
toxicities were tolerable. Nine patients (41%) never experienced
neutropenia. The median time to neutrophil engraftment for those
who experienced neutropenia was 10 days (range 2 to 20). The
overall survival for non-malignant transplant recipients was 100 %
and 43 % for patients with malignant disease, at a median fol-
low-up of 32 months (range, 4 to 73 months). Of the 8 patients
who died, 5 succumbed to relapse, while 1 died from infection, 1
from pulmonary and 1 from cardiac toxicity. Only one patient had
mild (grade I) acute graft-versus-host disease (aGVHD). We con-
clude that this reduced-intensity regimen enabled satisfactory en-
graftment and achievement of rapid complete donor chimerism
with minimal toxicities. It was associated with a low incidence of
aGHVD. The disease status was the main determinant of treat-
ment failure in this study.
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THE CONDITIONING REGIMEN INTENSITY OF ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (ALLO-HCT) IN CHRONIC MYELOID
LEUKEMIA (CML): THE HISTORICAL CASE MATCHED COMPARISON OF
ABLATIVE VERSUS REDUCED INTENSITY REGIMEN
Gurman, G.1, Arat, M.1, Topcuoglu, P.1, Caglayan, E.A.1, Arslan, O.1,
Ozcan, M.1, Akan, H.1, Beksac, M.1, Konuk, N.1, Uysal, A.1, Koc, H.1,
Ilhan, O.1 1Ankara University, School of Medicine, Department of
Hematology, Stem Cell Transplantation Unit, Ankara, Turkey.
Allo-HCT is the only curative treatment approach yet. The use
of reduced intensive conditioning (RIC) regimen, which has the
main advantage of decrease in regimen related toxicity in compar-
ison with myeloablative (MA) regimens, is rising both in our
country and throughout the world. In this study we aimed to
retrospectively investigate the efﬁcacy of RIC on early and late
allogeneic transplant outcome in CML patients.Twenty-ﬁve pa-
tients conditioned with RIC regimen were matched to 48 patients,
who received a myeloablative regimen. The main criteria for case
matching among our CML allo transplant cohort were the Grat-
wohl scoring system (Gratwohl A. Lancet. 1998 352(9134):1087-
92). The donors were HLA identical siblings and the graft sources
were peripheral hematopoietic cell (n67) or bone marrow (n6).
Pretransplantation disease status was CP1 (n17), CP2 (n2), and
advanced phase (AP; accelerated phase plus blastic crisis) (n6) in
RIC group, and CP1 (n37), CP2 (n2) and AP (n18) in MA
group. All but one patient in MA group received BU&CY, while
FLU-based regimes were used in RIC group. Median age was 39
years (range, 24-57) and M/F was 11/14 in the RIC group, and
median age was 38.5 years (19-53 ys) and M/F was 30/18 in MA
group. The transplant-related data are shown in Table. The fre-
quency grade and period of mucositis were lower in RIC. As
expected days on total parenteral nutrition and febrile neutopenia
episodes were seen infrequently in RIC compared to MA. How-
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